Fujifilm Holdings Corp · TSE:4901
Fujifilm — Q3 FY2024 Earnings Presentation
34 slides from Fujifilm's earnings presentation, Feb 6, 2025
Slide 1: Earnings Presentation: Financial Results for Q3 FY2024
Earnings Presentation Financial Results for Q3 FY2024 February 6, 2025 Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are manage ment’s current assumptions and beliefs based on currently available information. Such forward-l
Slide 2: Agenda
Agenda Consolidated Financial Results for Q3 FY2024 (October to December 2024) Earnings Highlights and Key Topics 1 Teiichi Goto, President, Representative Director & CEO FUJIFILM Holdings Corporation Financial Results and Business Summary by Operating Segment 2 Masayuki Higuchi, Director & Corporat
Slide 3: Q3 FY2024 Earnings Highlights and Key Topics
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Q3 FY2024 Earnings Highlights and Key Topics 01 FUJIFILM Holdings Corporation 3
Slide 4: Earnings Highlights for Q3 FY2024
Earnings Highlights Highlights Key Topics Q3 FY2024 FY2024 Forecast Appendices Earnings Highlights for Q3 FY2024 Consolidated Performance for Q3 FY2024 (October to December 2024) (Exchange rates for Q3: ¥152/US$ +¥4 YoY; ¥163/Euro +¥4 YoY) Net income Record high Revenue Record high Operating income
Slide 5: Earnings Highlights for Q3 FY2024: Full-year Forecast
Earnings Highlights Highlights Key Topics Q3 FY2024 FY2024 Forecast Appendices Earnings Highlights for Q3 FY2024 Full-year Consolidated Forecast for FY2024 (Exchange rates for full year: ¥152/US$; ¥164/Euro) Net income Record high Revenue Record high Operating income Record high attributable to FUJI
Slide 6: Key Topics: VISION2030 Follow-up 1/2 Semiconductor Materials - 1
Earnings Highlights Highlights Key Topics Q3 FY2024 FY2024 Forecast Appendices Key Topics : VISION2030 Follow-up 1/2 Semiconductor Materials - 1 Investing ¥170 billion in capital expenditures/R&D in the semiconductor materials business over the next three years to FY2026 to strengthen our global sup
Slide 7: Key Topics: VISION2030 Follow-up 1/2 Semiconductor Materials - 2
Earnings Highlights Highlights Key Topics Q3 FY2024 FY2024 Forecast Appendices Key Topics : VISION2030 Follow-up 1/2 Semiconductor Materials - 2 In response to robust demand for CMP slurries*1, an advanced semiconductor material, we will expand production capacity at the Kumamoto site and introduce
Slide 8: Key Topics: VISION2030 Follow-up 2/2 Medical Systems
Earnings Highlights Highlights Key Topics Q3 FY2024 FY2024 Forecast Appendices Key Topics : VISION2030 Follow-up 2/2 Medical Systems NURA Global Innovation Center, a new hub for health screening services, was opened in Kerala, India. It will serve as a strategic hub for medical staff training and ce
Slide 9: Q3 FY2024 Financial Results and Business Summary by Operating Segment
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Q3 FY2024 Financial Results and Business Summary by Operating Segment 02 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from fi
Slide 10: Financial Results for Q3 FY2024
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Financial Results for Q3 FY2024 (Billions of yen) Q3 9 months Impact of Constant- Impact of Constant- FY2023 FY2024 Change FY2023 FY2024 Change exchange rate currency basis exchange rate currency basis 766.9 Recor
Slide 11: Consolidated Revenue and Operating Income by Operating Segment
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 Consolidated Revenue and Operating Income by Operating Segment (Billions of yen) Q3 9 months Revenue FY2023 FY2024 Change FY2023 FY2024 Change Constant-currency basis Constant-currency basis Healthcare 2
Slide 12: Business Summary: Healthcare
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 (October to December 2024) Business Summary: Healthcare YoY Change Revenue fell mainly due to lower sales of medical equipment and materials to China in the Revenue Operating income Medical Systems. Oper
Slide 13: Business Summary: Electronics
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 (October to December 2024) Business Summary: Electronics YoY Change Revenue soared as the Semiconductor Materials successfully tapped into demand for Revenue Operating income advanced semiconductor mater
Slide 14: Business Summary: Business Innovation
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 (October to December 2024) Business Summary: Business Innovation YoY Change Revenue rose driven mainly by higher sales of digital transformation (DX)-related solutions in Revenue Operating income the Bus
Slide 15: Business Summary: Imaging
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 (October to December 2024) Business Summary: Imaging YoY Change Revenue Operating income Revenue and profit soared driven by solid sales of instant photo systems and digital ↑+13.4％ ↑+23.6％ cameras. (Bil
Slide 16: Consolidated Balance Sheets
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q3 FY2024 Consolidated Balance Sheets (Billions of yen) Change from Change from Mar. 2023 Mar. 2024 Dec. 2024 Mar. 2023 Mar. 2024 Dec. 2024 Mar. 2024 Mar. 2024 Cash and cash equivalents 268.6 179.7 216.2 36.5 Shor
Slide 17: Consolidated Cash Flow
Earnings Highlights Q3 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q1-Q3 FY2024 (April to December 2024) Consolidated Cash Flow Cash in Cash out Adjusted free cash flow excluding business acquisitions (Billions of yen) FY2022 FY2023 FY2024 (Billions of yen) 9 months 9 months 9 mo
Slide 18: Financial Forecast for FY2024
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Financial Forecast for FY2024 03 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, and in some
Slide 19: Full-year Forecast for FY2024
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Full-year Forecast for FY2024 (Billions of yen) FY2024 FY2024 FY2023 Change from Change from Previous forecast Revised forecast Actual FY2023 previous forecast (as of Nov. 7, 2024) (as of Feb. 6, 2025) Revenue 2,960.9 3,150.0 Record high 3,150
Slide 20: Financial Forecast by Operating Segment
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Financial Forecast by Operating Segment With regard to the operating income forecast by segment, the forcast for the Healthcare segment has been revised downwards due to lower sales in the Medical Systems and higher costs in the Bio CDMO, whil
Slide 21: Appendices: Financial Results for Q3 FY2024
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Appendices: Financial Results for Q3 FY2024 04 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the pas
Slide 22: Q3 / 9M Earnings
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Q3 / 9M Earnings (Billions of yen) Q3 9 months Revenue FY2023 FY2024 Change FY2023 FY2024 Change Constant-currency basis Constant-currency basis Healthcare 242.5 240.5 (2.0) (0.8%) (6.0) (2.5%) 690.7 712.6 21.9 +3.2% (5.2) (0.7%) Medical Syste
Slide 23: Quarterly Earnings
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Quarterly Earnings (Billions of yen) FY2023 FY2024 Revenue Q1 Q2 Q3 Q4 Q1 Q2 Q3 Healthcare 206.8 241.4 242.5 284.4 229.2 242.9 240.5 Medical Systems 140.1 164.6 164.7 190.2 157.7 166.9 162.6 Bio CDMO 40.9 50.5 50.3 61.8 47.1 48.1 51.3 LS Solut
Slide 24: Operating Income Analysis (Q3 FY2024 vs Q3 FY2023)
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Operating Income Analysis (Q3 FY2024 vs Q3 FY2023) (Billions of yen) Q3 (a) (b) FY2023 FY2024 Operation Raw Material （b-a) Operating Change FX FY2023 FY2024 Detail Actual Actual and others price One-time cost Q3 Q3 Segment Healthcare 18.4 10.6
Slide 25: Full-year Forecast for FY2024: Revenue by Business
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Full-year Forecast for FY2024 Revenue by Business (Billions of yen) FY2023 FY2024 FY2024 Change from Change from Actual Previous forecast Revised forecast previous year previous forecast (as of Nov 7, 2024) (as of Feb 6, 2025) Healthcare 975.1
Slide 26: Operating Income Analysis (Full-year forecast vs previous forecast)
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Operating Income Analysis (Full-year forecast vs previous forecast) (Billions of yen) Previous Revised (a) (b) forecast forecast Operation Raw Material （b-a) Operating Change FX Previous Revised Detail (Nov 7,2024) (Feb 6,2025) and others pric
Slide 27: Bio CDMO Profitability
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Bio CDMO Profitability (Q3 YoY; FY2024 Forecast vs FY2023 Results) Profitability (EBITDA margin) excluding one-time costs was at breakeven in Q3 due to higher costs incurred to strengthen quality assurance / regulatory compliance on a global b
Slide 28: Consolidated Revenue by Geographical Area
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Consolidated Revenue by Geographical Area (Billions of yen) FY2023 9 months FY2024 9 months Change Ratio (%) Ratio (%) Japan 34.9% 751.2 32.9% 765.6 14.4 +1.9% The Americas 22.1% 477.0 20.9% 487.2 10.2 +2.1% Europe 15.4% 331.9 16.9% 392.2 60.3
Slide 29: Capital Expenditure and Depreciation & Amortization
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Capital Expenditure and Depreciation & Amortization Capital Expenditure and Depreciation & Amortization (Billions of yen) (Billions of yen) 6,000 600.0 Q3 9 months Full Year FY2024 510.0 FY2023 FY2024 FY2023 FY2024 FY2023 Forecast Healthcare 9
Slide 30: R&D Expenses and SG&A Expenses
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices R&D Expenses and SG&A Expenses (Billions of yen) Ratio to revenue R&D Expenses｜SG&A Expenses 900.0 9,000 40.0% (Billions of yen) Q3 9 months Full Year 752.5 710.7 FY2024 FY2023 FY2024 FY2023 FY2024 FY2023 30.0% Forecast 600.0 6,000 Healthcare
Slide 31: Market Trend and Number of Employees
Earnings Highlights Q3 FY2024 FY2024 Forecast Appendices Market Trend and Number of Employees ▐ Exchange rates (average) / Raw material prices (average) FY2023 FY2024 Unit Q1 Q2 Q3 Q4 Full Year Q1 Q2 Q3 9 months Full Year US$ ￥/US$ 138 145 148 149 145 156 149 152 152 152 € ￥/€ 150 157 159 161 157 16
Slide 32: References
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifilm.com
Slide 33: FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation
Slide 34: FUJIFILM Value from Innovation
FUJIFILM Value from Innovation